Our mission is to develop therapies that empower the immune system to combat neurodegeneration and our team is focused on developing treatments for some of the most challenging diseases facing our society. By harnessing advancements in genetics, immunology and neuroscience, we are pioneering the development of potential therapies to counteract the devastating progression of neurodegeneration. We are supported in this mission by experienced and accomplished scientists and clinicians, a novel portfolio of programs, leading healthcare investors, and pharma company partners, who share in our commitment to bettering the lives of patients and realizing a world where we make brain disorders history. This role is based at Alector’s headquarters in South San Francisco, CA. Regular onsite presence is essential given the combination of hands-on laboratory work, scientific leadership, and close collaboration with multidisciplinary teams We are seeking a Senior Associate Scientist, Bioanalytical Sciences to support bioanalytical assay development and execution across Alector’s nonclinical and clinical programs. You will be a hands-on laboratory scientist responsible for independently developing, optimizing, troubleshooting, and qualifying bioanalytical assays while also managing selected activities performed at external CROs.
You will bring strong experience with ligand-binding assays for pharmacokinetic, immunogenicity and biomarker assessments, including independent, hands-on development of PK, anti-drug antibody (ADA) and/or biomarker assays in biological samples such as CSF, serum/plasma, and tissue lysates. You must also have direct bioanalytical experience supporting a range of therapeutic modalities, such as antibodies, bispecific antibodies, and/or conjugated siRNA/ASOs.
This is an individual-contributor position with no people-management responsibilities. You will work closely with colleagues across Research, Toxicology, Clinical Development, and external partners to generate high-quality bioanalytical data that supports program decisions.